Our Latest Research Published in International Journal of Pharmaceutics

Great news! The long-acting GLP-1 receptor agonist TE-8105 has achieved an innovative breakthrough in formulation development, successfully creating a more convenient sublingual delivery form! We are thrilled to announce the publication of our paper, entitled “Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice”, has been published in the latest issue of the International Journal of Pharmaceutics. This achievement not only demonstrates TE-8105’s innovative advantage in formulation technology but also further expands its potential applications in weight management and other chronic metabolic diseases, highlighting its significant value for future clinical treatment and product development. Link to article: https://doi.org/10.1016/j.ijpharm.2026.126752 Related News Link: https://news.gbimonthly.com/tw/invest/show.php?num=84685 https://www.ctee.com.tw/news/20260319700843-430504 https://udn.com/news/story/7241/9390590

The release as fetched from its publisher. immunwork.com ↗